期刊文献+

甲状腺微小乳头状癌颈部淋巴结转移危险因素分析 被引量:11

Analysis of risk factors for cervical lymph node metastasis in papillary thyroid microcarcinoma
在线阅读 下载PDF
导出
摘要 目的回顾性研究甲状腺微小乳头状癌(PTMC)颈部淋巴结转移的危险因素。方法收集2010年1月—2020年3月西安交通大学第一附属医院耳鼻咽喉头颈外科收治的1 363例PTMC患者的临床资料,分析其性别、年龄、肿瘤直径、多灶性、腺外侵犯(ETE)、肿瘤侧别、颈淋巴结转移、BRAF~(V600E)突变与颈淋巴结转移的关系。结果单因素分析显示男性、年龄<55岁、肿瘤直径>5 mm、多灶ETE、双侧癌灶与PTMC颈部淋巴结转移相关(P均<0.05);进一步统计分析显示男性、年龄<55岁、肿瘤直径>5 mm、多灶、ETE、双侧癌灶患者易发生中央区淋巴结转移(P均<0.05);男性、多灶、ETE、双侧癌灶患者更易发生颈侧区淋巴结转移(P<0.05)。Logistic回归分析显示男性、年龄<55岁、肿瘤直径>5 mm、多灶和ETE是PTMC颈部淋巴结转移的独立危险因素(P均<0.05);进一步统计分析显示其同时也是中央区淋巴结转移的独立危险因素(P<0.05);而颈侧区淋巴结转移的独立危险因素为男性、多灶和ETE(P均<0.05)。结论 PTMC患者如果同时存在男性、年龄<55岁、肿瘤直径>5 mm、多灶和ETE等淋巴结转移危险因素时,建议常规行中央区颈淋巴结清扫术,同时结合术前颈部B超或增强CT结果,考虑行选择性颈侧区淋巴结清扫,降低肿瘤复发再次手术的风险;其余PTMC患者可建议定期复查甲状腺B超密切随诊。 Objective To explore the risk factors for cervical lymph node metastasis in papillary thyroid microcarcinoma(PTMC).Methods Clinical data of 1363 PTMC patients were treated surgically from Jan.2010 to Mar.2020 the First Affiliated Hospital of Xi’an Jiaotong University,otolaryngology head and neck.The clinicopathological features between the two groups,including patients’gender and age,tumor size,multiple foci,extrathyroidal extensive(ETE),tumor location,cervical lymph node metastasis,as well as the relationship between BRAF V600E mutation and cervical lymph node metastasis,were compared and analyzed.Results Univariate analysis showed that cervical lymph node metastasis was associated with male gender,age<55 years old,tumor diameter>5 mm,multiple foci,ETE and bilateral cancer(all P<0.05).Further analysis showed that central lymph node metastasis was most likely to occur in patients with male gender,age<55 years old,tumor diameter>5 mm,multiple foci,ETE,bilateral cancer(all P<0.05).Male patients with multiple foci,ETE and bilateral cancer were prone to lateral lymph node metastasis(all P<0.05).Logistic regression analysis showed that male gender,age<55 years old,tumor diameter>5 mm,multiple foci and ETE were independent risk factors for both cervical lymph node metastasis(all P<0.05)and central lymph node metastasis(all P<0.05).However,the independent risk factors for lateral lymph node metastasis were male gender,multiple foci and ETE(all P<0.05).Conclusions In PTMC patients with risk factors for lymph node metastasis such as male gender,age<55 years old,tumor diameter>5 mm,multifoci and ETE,preventive dissection of central lymph node should be routinely performed,and selective lateral lymph node dissection should be considered in combination with preoperative cervical B ultrasonography or enhanced computed tomography to reduce the risk of recurrence.Periodic B ultrasound thyroid examination and close follow-up are recommended for other PTMC patients.
作者 任婉丽 戴皓 杨邡俪 陈佳钰 杨鸣 裴蓓 韩鹏 邵渊 白艳霞 REN Wanli;DAI Hao;YANG Fangli;CHEN Jiayu;YANG Ming;PEI Bei;HAN Peng;SHAO Yuan;BAI Yanxia(Department of Otolaryngology Head and Neck Surgery,the First Affiliated Hospital of Xi’an Jiaotong University,Xi’an 710061,China)
出处 《中国耳鼻咽喉颅底外科杂志》 CAS 2021年第1期6-11,共6页 Chinese Journal of Otorhinolaryngology-skull Base Surgery
关键词 头颈肿瘤 甲状腺微小乳头状癌 颈部淋巴结转移 危险因素 Head and neck tumor Papillary thyroid microcarcinoma Cervical lymph node metastasis Risk factor
  • 相关文献

参考文献2

二级参考文献51

  • 1American Thyroid Association (ATA) Guidelines Taskforce on Thy- roid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American thyroid association manage- ment guidelines for patients with thyroid nodules and differentiat- ed thyroid cancer[J]. Thyroid, 2009, 19(11):1167-1214.
  • 2Haugen BR, Alexander EK, Bible KC, et al. 2015 American thyroid as- sociation management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid as- sociation guidelines task force on thyroid nodules and differentiat- ed thyroid cancer[J]. Thyroid, 2016, 26(1):1-133.
  • 3Tuttle RM, Haddad RI, Ball DW, et al. Thyroid carcinoma, version 2.2014[J]. J Natl Compr Canc Netw, 2014, 12(12):1671-1680.
  • 4Xing MZ. Molecular pathogenesis and mechanisms of thyroid can- cer[J]. Nat Rev Cancer, 2013, 13(3):184-199.
  • 5De Biase D, Gandolfi G, Ragazzi M, et al. TERT promoter mutations in papillary thyroid microcarcinomas[J]. Thyroid, 2015, 25(9):1013- 1019.
  • 6Ito Y, Miyauchi A, Inoue H, et al. An observational trial for papillary thyroid microcarcinoma in Japanese patients[J]. World J Surg, 2010, 34(1):28-35.
  • 7Ito Y, Uruno T, Nakano K, et al. An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid [J]. Thyroid, 2003, 13(4):381-387.
  • 8Xing M, Alzahrani AS, Carson KA, et al. Association between BRAF V600E mutation and recurrence of papillary thyroid cancer[J]. J Clin Oncol, 2015, 33(1):42-50.
  • 9Jiang LH, Chen C, Tan Z, et al. Clinical characteristics related to central lymph node metastasis in cN0 papillary thyroid carcinoma: a retro- spective study of 916 patients[J]. Int J Endocrinol, 2014, 2014:385787.
  • 10Ito Y, Fukushima M, Higashiyama T, et al. Tumor size is the strongest predictor of microscopic lymph node metastasis and lymph node recurrence of NO papillary thyroid carcinoma[J]. Endocr J, 2013, 60 (1):113-117.

共引文献480

同被引文献109

引证文献11

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部